De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy.
Centre de Référence Malformations Cardiaques Congénitales Complexes-M3C Hôpital Necker Enfants Malades, APHP Paris Cité, Paris, France.
JACC Heart Fail. 2022 Oct;10(10):714-727. doi: 10.1016/j.jchf.2022.06.013. Epub 2022 Sep 7.
The risk of adverse cardiovascular events in patients with acute myocarditis (AM) and desmosomal gene variants (DGV) remains unknown.
The purpose of this study was to ascertain the risk of death, ventricular arrhythmias, recurrent myocarditis, and heart failure (main endpoint) in patients with AM and pathogenic or likely pathogenetic DGV.
In a retrospective international study from 23 hospitals, 97 patients were included: 36 with AM and DGV (DGV[+]), 25 with AM and negative gene testing (DGV[-]), and 36 with AM without genetics testing. All patients had troponin elevation plus findings consistent with AM on histology or at cardiac magnetic resonance (CMR). In 86 patients, CMR changes in function and structure were re-assessed at follow-up.
In the DGV(+) AM group (88.9% DSP variants), median age was 24 years, 91.7% presented with chest pain, and median left ventricular ejection fraction (LVEF) was 56% on CMR (P = NS vs the other 2 groups). Kaplan-Meier curves demonstrated a higher risk of the main endpoint in DGV(+) AM compared with DGV(-) and without genetics testing patients (62.3% vs 17.5% vs 5.3% at 5 years, respectively; P < 0.0001), driven by myocarditis recurrence and ventricular arrhythmias. At follow-up CMR, a higher number of late gadolinium enhanced segments was found in DGV(+) AM.
Patients with AM and evidence of DGV have a higher incidence of adverse cardiovascular events compared with patients with AM without DGV. Further prospective studies are needed to ascertain if genetic testing might improve risk stratification of patients with AM who are considered at low risk.
患有急性心肌炎(AM)和桥粒蛋白基因突变(DGV)的患者发生不良心血管事件的风险尚不清楚。
本研究旨在确定患有 AM 和致病性或可能致病性 DGV 的患者的死亡、室性心律失常、复发性心肌炎和心力衰竭(主要终点)的风险。
在一项来自 23 家医院的回顾性国际研究中,纳入了 97 名患者:36 名患有 AM 和 DGV(DGV[+]),25 名患有 AM 和阴性基因检测(DGV[-]),36 名患有 AM 但未进行基因检测。所有患者均有肌钙蛋白升高,组织学或心脏磁共振(CMR)检查发现符合 AM 的表现。在 86 名患者中,在随访时重新评估了功能和结构的 CMR 变化。
在 DGV(+)AM 组(88.9%DSP 变异)中,中位年龄为 24 岁,91.7%的患者出现胸痛,CMR 检查的左心室射血分数(LVEF)中位数为 56%(与其他 2 组相比无统计学意义;P=NS)。Kaplan-Meier 曲线显示,与 DGV(-)和未进行基因检测的患者相比,DGV(+)AM 患者的主要终点风险更高(分别为 5 年时的 62.3%、17.5%和 5.3%;P<0.0001),这主要是由心肌炎复发和室性心律失常引起的。在随访 CMR 中,DGV(+)AM 患者的晚期钆增强节段数量更多。
与无 DGV 的 AM 患者相比,患有 AM 和 DGV 证据的患者发生不良心血管事件的风险更高。需要进一步的前瞻性研究来确定基因检测是否可以改善被认为低风险的 AM 患者的风险分层。